Edwards Lifesciences Corp (EW)vsPAVmed Inc (PAVM)
EW
Edwards Lifesciences Corp
$82.67
+1.20%
HEALTHCARE · Cap: $48.01B
PAVM
PAVmed Inc
$9.30
+1.09%
HEALTHCARE · Cap: $9.06M
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 20922659% more annual revenue ($6.07B vs $29,000). PAVM leads profitability with a 106.7% profit margin vs 17.7%. EW earns a higher WallStSmart Score of 55/100 (C).
EW
Buy55
out of 100
Grade: C
PAVM
Hold35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-544.4%
Fair Value
$12.31
Current Price
$82.67
$70.36 premium
Intrinsic value data unavailable for PAVM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 23.7%
Reasonable price relative to book value
Keeps 107 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 76.6%
0.0% earnings growth
Smaller company, higher risk/reward
Revenue declined 99.5%
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.
Bull Case : PAVM
The strongest argument for PAVM centers on Price/Book, Profit Margin, Debt/Equity. Profitability is solid with margins at 106.7% and operating margin at -968.8%.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.7x leaves little room for execution misses.
Bear Case : PAVM
The primary concerns for PAVM are EPS Growth, Market Cap, Revenue Growth.
Key Dynamics to Monitor
EW profiles as a mature stock while PAVM is a declining play — different risk/reward profiles.
EW carries more volatility with a beta of 0.93 — expect wider price swings.
EW is growing revenue faster at 13.3% — sustainability is the question.
EW generates stronger free cash flow (354M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 35/100), backed by strong 17.7% margins and 13.3% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →PAVmed Inc
HEALTHCARE · MEDICAL DEVICES · USA
PAVmed Inc. is a medical device company in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?